netFormulary NHS
Cambridgeshire and Peterborough

Looking for Alemtuzumab found 8 matches

Formulary BNF Category
  Restricted Drug  Alemtuzumab  (Lemtrada)
Anti-lymphocyte monoclonal antibodies - 08.02.03
  Restricted Drug  Alemtuzumab Off-Label Use of Medicines - 20.01

Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section CUHFT SCG: Alemtuzumab for treating relapsing-remitting multiple sclerosis (monitoring only) (08.02.03)
link in drug section Letters sent to healthcare professionals February 2020: Lemtrada▼ (alemtuzumab) - Restricted indication, additional contraindications and risk minimisation measures (08.02.03)
link in drug section MHRA Drug Safety Update February 2020: Lemtrada▼ (alemtuzumab) - updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions  (08.02.03)
link in drug section MHRA Drug Safety Update May 2019: Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions - new restrictions to use and strengthened monitoring requirements (08.02.03)
link in drug section MHRA Letters and drug alerts sent to healthcare professionals April 2019: Alemtuzumab (Lemtrada) - Restriction of use due to serious safety concerns (08.02.03)
link in drug section NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis (08.02.03)